In contrast to the effects of synthetic retinoids, increasing doses of atRA caused increasing PML-RARA degradation in APL mice, which correlated with survival benefits both for the treated mice and for secondary recipients [68]. This evidence concerns the gene RARA and acute promyelocytic leukemia.